UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Apple Restores Telegram to App Store After Content Policy Violation 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
WINDSOR, Conn., March 26, 2018 -- Scapa Healthcare, a trusted strategic outsource partner of skin-friendly, turnkey solutions, today announced the acquisition of Dallas, TX-based BioMed Laboratories. BioMed is a leading business-to-business developer and manufacturer of topical skin care solutions for advanced wound care, ostomy and consumer wellness markets.
Serving similar customer bases, BioMed is Scapa Healthcare’s first adjacent platform. The acquisition broadens Scapa’s offerings beyond adhesive-based solutions to now include complementary skin care offerings such as tubed hydrogel, wound cleansers, moisturizers and more. BioMed’s portfolio of products includes gels, creams, lotions, liquids, powders and hot fill waxes.
The addition of BioMed strengthens Scapa Healthcare’s offerings to its customers in the advanced wound care and ostomy markets, and expands market accessibility within consumer wellness segments such as OTC, first aid and health and beauty.
“At Scapa Healthcare, we remain committed to being the trusted strategic outsource partner of choice for our customers,” said Joe Davin, President Scapa Healthcare. “The acquisition of BioMed is in line with our continued growth strategy. We continue to expand our capabilities and product offerings while maintaining the level of excellence our partners expect.”
BioMed’s quality system is certified to ISO 13485 standards, and complies with FDA cGMP, Health Canada and EU regulatory requirements.
For more information on the acquisition, please visit http://www.scapa.com/en/news/AcquisitionofBioMedLaboratoriesLLC.
Learn more about BioMed Laboratories
About Scapa Healthcare
Scapa Healthcare is a global trusted strategic outsource partner of skin-friendly turnkey solutions for advanced wound care, consumer wellness and medical device markets. Scapa Healthcare partners with market leaders to design, develop, manufacture and commercialize innovative skin contact solutions to meet end-user needs. Scapa Healthcare offers turn-key development services, including design and project management; coating; converting, perforation and assembly; printing and packaging; and sterilization services. For more information, visit: www.scapahealthcare.com
Media Contact Jordan Bouclin SVM Public Relations and Marketing Communications [email protected] (401) 490-9700 Scapa Healthcare Contact Scapa Healthcare Marketing Communications Manager [email protected] (860) 902-8157
